2022.11.03
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.
Press Releases
2022.10.05
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
I-Mab will present new preclinical data of its core assets lemzoparlimab and uliledlimab at the 37th SITC Annual Meeting.
2022.09.13
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
Media Reports
2022.02.03
Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection
Read at Endpoints2021.07.09
FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations
Read at FierceBiotech2021.05.19
2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody
Read at EndpointsPartner News
2021.07.09
2021.06.29
2020.11.09